Continuous blood glucose measurements: The acute effect of acarbose of the blood glucose amplitudes;Kontinuierliche blutglucosemessungen: Der akuteffekt von acarbose auf die blutglucoseschwankungen

Medizinische Klinik

Volumn 93, Issue 11, 1998, Pages 651-655

  Herrmann, Burkhard Lorenz ^a   Schatz, Helmut ^b   Pfeiffer, Andreas ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Universitatsklinik

Author keywords

Acarbose; Blood glucose amplitudes; Continuous blood glucose monitoring; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; CARBOHYDRATE; FRESUBIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; SULFONYLUREA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CARBOHYDRATE INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DRUG EFFECT; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; SENSOR;

EID: 0031791373     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044876     Document Type: Article

References (28)

1. Aubell R, Boehrne K, Berchtold P. Blood glucose concentrations and glycosuria during and after one year of acarbose therapy Arzneim Forsch 1993;33:1314-8.
2. Balfour JA, McTavish D. Acarbose. An uptake of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993;46.1025-54.
3. Baron A, Eckel R, Schmeiser L, et al. The effect of short-term α-glucosidase inhibition on carbohydrate and hpid metabolism in type-2 (noninsulin-dependent)-diabetics. Metab Clin Exp 1987;36-409-15.
4. Büber V, Effect of acarbose in non-insulin-dependent diabetic patients during long-term treatment. In: Creutzfeldt W, ed. Acarbose: Effects on carbohydrate and fat metabolism. Amsterdam-Oxford-Princeton: Experta Medica, 1982:266-74.
5. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994;121:928-35.
6. ConiffRF, Shapiro JA, Seaton TB. Longterm efficacy and safty of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 1994;154 2442-8.
7. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM Diab Care 1992;15:318-53.
8. R. Domke A, Willms B. Wirksamkeit und Verträglichkeit etner längerfristigen Acarbosetherapie bei Diabetikern mit drohendem Sekundärversagen einer Sulfonylharnstoflbe-handlung. Med Klin 1994;89:187-92.
9. Göke B, Herrmann C, Göke R, et al Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. EurJ Clin Invest 1994;24:25-30.
10. Hanefeld M, Fischer S, Schulze J, et al. Therapeutical potentials of acarbose as first line drug in non-insulin-dependent diabetes insufficiently treated with diet alone. Diab Care 1991;14:732-7.
11. Heikler FR, Böshagen H, Junge B, et al. Studies designed to localize the essential structural unit of glycoside-hydrolase inhibitors of the acarbose type. In: Creutzfeldt W, ed. Acarbose: Effects on carbohydrate and fat metabolism. Amsterdam-Oxford-Princeton: Experta Medica, 1982.137-41.
12. Heuer LJ von, Kaufmann HH Zur Wirkung von Acarbose auf Kohlenhydrat- und Fettstoffwechsel bei Sekundarversagenden Typ-2-Diabetes. Dtsch Z Verdau Stoffw 1985;45:52-8.
13. Laube HR, Aubell R, Schmitz H, et al. Acarbose, an effective therapy in lowering postprandial hyperglycaemia in obese patients with type-2-diabetes mellitus. In: Creutzfeldt W, ed. Acarbose: Effects on carbohydrate and fat metabolism. Amsterdam-Oxford-Princeton: Experta Medica, 1982:345-7.
14. Ledermann H, Höxter G. Wirkung von Acarbose auf den postprandialen. Blutzuckeranstieg. Additiver Akuteffekt der einmal täglichen Gabe bei insulinbehandelten Diabetikern. Fortsch Med 1994;112:467-70.
15. Leonardt W, Hanefeld M, Fischer S, et al. Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment Arzneim Forsch 1991;41:735-8.
16. May B, Huppe D. Efficacy and tolerability of a 3-month treatment with acarbose in typ II diabetic outpatients treated with a high dose of sulfonylurea. In: Creutzfeldt W, ed. Acarbose for the treatment of diabetes mellitus. Berlin-Heidelberg-New York: Springer, 1983:124.
17. Muller L. Microbial glycosidase inhibitors. In: Rehm HJ, Reed G, ed. Biotechnology. Weinheim: VCH Verlagsgesellschaft, 1985:531-68.
18. Müller U, Hintze G, Spengler M, et al. Effekt von Acarbose auf Blutglucosekonzentration und Insulinkonzentration bei adipösen Typ-2-Diabetikern unter hypokalorischer Diät. Diab Stoffw 1993;2:168.
19. Orimo H, Akiguchi I, ShirakiM. Usefulness of acarbose in the management of the non-insulin-dependent diabetes in the aged. In: Creutzfeldt W, ed. Acarbose: Effects on carbohydrate and fat metabolism. Amsterdam-Oxford-Princeton: Experta Medica, 1982:348-52.
20. Pfeiffer EF. Glucose sensors in tissue, glucose monitoring and controlled insulin administration. Med Klin 1996;91:Suppl 1:12-5.
21. Pfeiffer EF, Meyerhoff C, Bischof F, et al. On line continuous monitoring of subcutaneous tissue glucose is feasible by combining portable glucosensor with microdialysis. Horm Metab Res 1993;25:121-4.
22. Puls W, Keup U, Krause HP, et al. Glucosidase inhibition. A new approach of the treatment of diabetes, obesity, and hyperlipoproteinaemia. Naturwiss 1977;64:536-7.
23. Qualmann C, Nauck MA, Holst JJ, et al. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995;30:892-6.
24. Rios MS. Acarbose and insulin therapy in type I diabetes mellitus. EurJ Clin Invest 1994;24:Suppl 3:36-9.
25. Sachse G, Mäser E, Laube H, et al. Diabetische Stoffwechsellage unter längerfristiger Acarbosetherapie. The-rapiewoche 1982;32:3587-90.
26. Sachse G, Willms B. Effect of the α-glucosidase inhibitor Bay-g-5421 on blood glucose control of sulfonylurea-treated diabetics and insulin-treated diabetics. Diabetologia 1979;17:287-90.
27. Spengler M, Hänsel G, Boehme K. Efficacy of 6 months monotherapy with glucosidase inhibitor acarbose versus sulphonurea glibenclamide on metabolic control of dietary treated type II diabetics (NIDDM). Horm Metab Res 1992;Suppl:50-1.
28. Yee HS, Fong NT. A review of the safety and efficacy of acarbose in diabetes mellitus. Pharmacotherapy 1996;16: 792-805.